Highlights Sanofi

Equities

SAN

FR0000120578

Real-time Euronext Paris Other stock markets 06:55:30 2024-06-06 am EDT			5-day change	1st Jan Change
90.17 ^EUR	-0.57%		+1.81%	+0.46%

Jun. 05	Lupin Arm Acquires Two Brands from Sanofi in Europe and Canada	MT
Jun. 05	Lupin Atlantis Holdings SA completed the acquisition of selection of established products in Europe and Canada from Sanofi.	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lupin Arm Acquires Two Brands from Sanofi in Europe and Canada	Jun. 05	MT
Lupin Atlantis Holdings SA completed the acquisition of selection of established products in Europe and Canada from Sanofi.	Jun. 04	CI
CAC40: losses trimmed as oil falls below $78 and interest rates ease	Jun. 04	CF
Charles River Laboratories, Sanofi Collaborating to Develop Non-Animal Virtual Control Groups for Preclinical Trials	Jun. 04	MT
Sanofi: positive phase III data in myeloma	Jun. 04	CF
Sanofi's Blood Cancer Drug Sarclisa Meets Primary, Secondary Endpoints in Phase 3 Trial	Jun. 04	MT
DHL Strikes Logistics Partnership with Sanofi	Jun. 03	MT
GSK shares tumble 9% after 70,000 Zantac lawsuits allowed to proceed	Jun. 03	RE
Sanofi Enlists Banks for EUR20 Billion Consumer Health Spinoff, IPO	Jun. 03	MT
GSK Plans Appeal Against US Judge's Ruling on Jury Trials for Zantac Cases	Jun. 03	MT
Sanofi Moving Ahead With EUR20Bln Consumer Healthcare Spinoff, FT Reports	Jun. 03	DJ
Sanofi Enlists Banks for EUR20 Billion Consumer Health Spinoff, IPO	Jun. 02	MT
Delaware judge lets more than 70,000 Zantac lawsuits go forward	Jun. 01	RE
CAC40: remains at equilibrium despite sharp decline in Nasdaq and S&P	May. 31	CF
CAC40: May ends with no trend and a zero score	May. 31	CF
EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review	May. 31	RE
Sanofi: launch of employee share ownership plan 2024	May. 31	CF
Regeneron Pharmaceuticals, Sanofi Say Dupixent FDA Application Decision Delayed by 3 Months	May. 31	MT
Regeneron Pharmaceuticals, Inc and Sanofi Announce Dupixent® Recommends for EU Approval by the CHMP to Treat Patients with COPD	May. 31	CI
Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® for the Treatment of COPD Patients with Type 2 Inflammation	May. 31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

SANOFI : Sanofi’s healthy Q1 performance hailed by markets

April 25, 2024 at 07:58 am EDT

Sanofi Sees Trend for Years of Steady Growth: CFO

February 03, 2023 at 03:56 pm EST